Table 1.
Patient characteristics
| Characteristic | Eligible patients N=40 | Evaluable patients N=28 | |
|---|---|---|---|
| Age in years-Median (range) | 58 (40-76) | 59 (50-73) | |
| Race-N (%) | European American | 22 (55%) | 16 (57%) |
| African American | 16 (40%) | 11 (39%) | |
| Middle Eastern | 1 (3%) | 0 (0%) | |
| Other | 1 (3%) | 1 (4%) | |
| Performance status-N (%) | ECOG 0 | 40 (100%) | 28 (100%) |
| Pre-treatment PSA (ng/mL)-Median (range) | 6.4 (2.1-29.4) | 6.4 (2.1-20.5) | |
| Testosterone (ng/mL)-Median (range) | 301 (77-608) | 292 (77-557) | |
| Gleason sum from biopsy-N (%) | 6 | 17 (44%) | 11 (39%) |
| 7 | 21 (53%) | 16 (57%) | |
| ≥ 8 | 2 (5%) | 1 (4%) | |
| Clinical T stage-N (%) | T1c | 30 (75%) | 20 (71%) |
| T2a | 5 (13%) | 3 (11%) | |
| T2b | 3 (8%) | 3 (11%) | |
| T2c | 2 (5%) | 2 (7%) | |
| Clinical N stage-N (%) | N0 | 11 (28%) | 8 (29%) |
| NX | 29 (73%) | 20 (71%) | |
| Gleason sum from surgical specimen-N (%) | 6 | 11 (28%) | 7 (25%) |
| 7 | 26 (65%) | 20 (71 %) | |
| ≥ 8 | 2 (5%) | 1 (4%) | |
| unknown | 1 (3%) | 0 (0%) | |
| Pathologic T stage-N (%) | T2a | 2 (5%) | 1 (4%) |
| T2c | 23 (58%) | 16 (57%) | |
| T3a | 10 (25%) | 8 (29%) | |
| T3b | 4 (10%) | 3 (11%) | |
| TX | 1 (3%) | 0 (0%) | |
| Pathologic N stage-N (%) | N0 | 33 (85%) | 24 (86%) |
| NX | 7 (18%) | 4 (14%) |